Head and Neck Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have received radiation therapy combined with cetuximab (a targeted cancer drug) following a specific treatment approach known as the Bonner protocol
- People who have received cetuximab combined with chemotherapy following a specific treatment approach known as the Vermorken protocol
- People who have received a molecularly targeted cancer drug as part of another clinical study
Who may not be able to join:
- People who have a type of head and neck cancer other than the type this trial is focused on (confirm with trial site)
- People who have not been treated with any targeted cancer therapies
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jean-Pascal Machiels, MD, PhD, Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phone: 0032 2 764
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Prospective storage of plasma samples of patients treated with cetuximab or other targeted agents
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.